Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Human CD30/TNFRSF8 (Research Grade Brentuximab Biosimilar) Alexa Fluor 700-conjugated Antibody, R&D Systems™
GREENER_CHOICE

Human Monoclonal Antibody

Supplier:  R&D Systems FAB9576N100UG

Catalog No. FAB9576N100


Only null left
Add to Cart
This item is not returnable. View return policy

Description

Description

CD30/TNFRSF8 Monoclonal specifically detects CD30/TNFRSF8 in Human samples. It is validated for Flow Cytometry.
Specifications

Specifications

CD30/TNFRSF8
Monoclonal
Alexa Fluor 700
Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
Human
Protein A or G purified from cell culture supernatant
Primary
Detects human CD30/TNFRSF8 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Brentuximab. This product is for research use only.
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 degreesC as supplied.
IgG1
Flow Cytometry
Hu8
Flow Cytometry 0.25-1 ug/10^6 cells
CD30, CD30 antigen, CD30KI-1, CD30L receptor, cytokine receptor CD30, D1S166EKi-1, Ki-1 antigen, Lymphocyte activation antigen CD30, TNFRSF8, tumor necrosis factor receptor superfamily member 8, tumor necrosis factor receptor superfamily, member 8
Human CD30/TNFRSF8
100 μg
943
Human
Supernatant
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.